

Diseases of the Pancreas Jack Bragg DO, MACOI


# I have no disclosures

## I work for the Curators of the University of Missouri











# **Etiologies**



- Autoimmune
- Drug-induced
- latrogenic
- IBD-related
- Infectious
- Inherited
- Metabolic
- Neoplastic
- Structural
- Toxic
- Traumatic
- Vascular







**Sphincter of Oddi Dysfunction** 

# **Modified Biliary Classification**

A = Elevated liver tests on 1 or more occasions **B** = Dilated Common Bile Duct **Biliary Type I – A+B Biliary Type II – A or B** Biliary Type III – Pain only




## **Drug Induced Pancreatitis Sorted by Incidence**


Common asparaginase azathioprine 6-mercaptopurine didanosine (DDI) pentamidine valproate

Uncommon **ACE** inhibitors acetaminophen **5-amino ASA** furosemide sulfasalazine thiazides

Rare carbamazepine corticosteroids estrogens minocycline nitrofurantoin tetracycline








# Local Effects of Enzymes

Inflammation
Third space losses
Fat necrosis
Pancreatic and peripancreatic necrosis

#### Danger Signals: First Few Hours



- Encephalopathy
- Hypoxemia
- Tachycardia >130/min
- Hypotension <90 mmHg</p>
- Hct >50
- Oliguria <50 ml/hr</p>
- Azotemia





#### Figure 1.

(A) Periumbilical ecchymosis (Cullen sign) and(B) flank ecchymosis (Grey Turner sign). Publishedwith permission from Chung and Chuang.<sup>1</sup>



### Grey-Turner Sign



## Ranson's Criteria of Severity


#### At admission

- Age >55 years
- WBC >16,000/mm<sup>3</sup>
- Glucose >200 mg/dl
- LDH >350 IU/L
- AST >250 U/L

#### During initial 48 hours

- Hct decrease of >10
- BUN increase of >5 mg/dl
- Ca\*\* <8 mg/dl</p>
- PaO<sub>2</sub> <60 mm Hg</p>
- Base deficit >4 mEq/L
- Fluid sequestration >6 L





## Treatment


#### Supportive care

- Aggressive fluid and electrolyte replacement
- Monitoring Vital signs
   Urine output
   O<sub>2</sub> saturation
   Pain
- Analgesia, anti-emetics

## **Other treatments**

- Acid suppression
- Antibiotics
- NG tube
- Nutritional support
- Urgent ERCP





# **Nutritional Support**

 Consider when protracted course is likely

 Enteral vs parenteral Safety
 ? Effect on outcome

 Monitor calcium and triglycerides





# **Major Complications**

## Local

- Fluid collections
- Necrosis
- Infection
- Ascites
- Erosion into adjacent structures
- GI obstruction
- Hemorrhage

# Systemic

- Pulmonary
- Renal
- CNS
- Multiorgan failure

## **Metabolic**

- Hypocalcemia
- Hyperglycemia




# Causes of mortality DEATH

Late (> one week)

- Multiorgan failure
- Pancreatic infections/sepsis

Early (< one week)


- Systemic inflammatory response syndrome (SIRS)
- Multiorgan failure




#### Reduction of Inflammation: Proposed Methods

 Remove impacted gallstones (papillotomy) Remove ascites (peritoneal lavage) Remove circulating proteases protease inhibitors fresh frozen plasma plasmapheresis stimulation of monocyte-macrophage system Remove O<sub>2</sub>-derived free radicals

## Progression to Pseudocyst






PSEUDOCYST


## Complications

Severe pain Obstruction (CBD, duodenum) Dissection Bleeding Infection Leakage (ascites, pleural effusion) Rupture



**Acute Pancreatitis: Necrosis** 

## Progression










#### **Pancreatic Necrosis**




## Non-perfusion

## Systemic complications

 Local complications Hemorrhage Infection



#### **Pancreatic Necrosis**



# Debridement

vs Observation



## Signs of Infected Pancreatic Necrosis


 Increasing markers of inflammation (serum CRP, white blood cell count)

 Newly developed fever without extra pancreatic infection

 Signs of infection on CT (gas collection within areas of necrosis)




# Necrosis











#### **Pancreatic Necrosis**

## **Treatment Strategies**

Sterile

Medical therapy


 Debridement for persistent organ failure? Infected

Antibiotics

Debridement










# **Chronic Pancreatitis**

Pain
Calcification
Pancreatic insufficiency


#### CHRONIC PANCREATITIS



#### Diabetes

Loss of insulin and glucagon


- Only in severe disease
- Brittle
- Insulin requirement low
- Ketoacidosis rare




# **Clinical Assessment**

Presentation	Order of evaluation
Pain	Imaging
Malabsorption	Imaging Trial of pancreatic enzymes Tests of pancreatic insufficiency






#### CHRONIC PANCREATITIS











### **Splenic Vein Thrombosis**



- Associated with chronic disease
- Splenomegaly
- Large gastric varices without esophageal varices
- Splenectomy for bleeding



# Cystic Neoplasm



#### **Clinical clues**

- No prior pancreatitis
- Unexplained pancreatitis
- Cyst present on 1<sup>st</sup> CT

#### Diagnosis

- Fluid analysis
- EUS, ERCP
- Resection



#### **Cystic Pancreatic Lesions**

Туре	Features	Cancer risk
Pseudocyst	Macrocystic Thick wall	None
Serous cystadenoma	Micro- or macrocystic	Low
Mucinous cystadenoma	Macrocystic	High
Mucinous cystadenocarcinoma	Macrocystic Thick wall Intracystic mass	Cancer present






### Nutritional Management of Exocrine Insufficiency

Diet and exogenous enzymes Modify fat intake Medium chain triglycerides Enzyme replacement

- Coated vs uncoated
- Acid suppression





Vitamins, supplements Fat soluble Calcium Cyanocobalamin (B<sub>12</sub>)



# Pain Management

Treatment	Effectiveness	
No alcohol	Low to moderate	
Analgesia	Moderate	
Enzyme replacement	Low	
Neurolytic therapy	Moderate short term	
Pseudocyst drainage	High	
Duct decompression	Moderate	
•		



### Use of Exogenous Enzymes for Pain

Study	Preparation	Response
lsaksson (1983)	uncoated	yes
Slaff (1984)	uncoated	yes
Halgreen (1986)	coated	no
Mossner (1992)	coated	no
Malesci (1995)	coated	no





# Steatorrhea

# Stool with excessive fat



### Sudan stain


### Mechanisms


- Decreased concentration of lipase and colipase
- Duodenal pH
  - Inactivation of pancreatic lipase pH<4.5
  - Precipitation of bile salts



### **Pancreatic Cancer Risk**

#### 3-15 fold increase









Lowenfels, et al., N Engl J Med 1993; 328:1433

#### Pancreatic Insufficiency Without Pancreatitis

#### Non-pancreatic

- Mucosal disease
  - $\downarrow$  CCK release
  - Enterokinase deficiency \*
- Gastrinoma
- Bilroth II reconstruction

#### Pancreatic

- Cystic fibrosis \*
- Pancreatic tumors
- Shwachman-Diamond syndrome \*
- Childhood pancreatic atrophy \*
- Johanson-Blizzard syndrome\*
- Adult lipomatosis or atrophy
- Protein-calorie malnutrition





# **Diagnostic Criteria: I**

Imaging

Diffuse pancreatic duct narrowing Diffuse pancreatic enlargement

Immunity Autoantibodies Elevated gammaglobulins or IgG4

Histology

Periductular lymphoblastic infiltrate Phlebitis

Fibrosis





#### **Autoimmune Pancreatitis**

### **Presentation**

#### Symptoms

- Asymptomatic or mild pain
- Acute pancreatitis, rare
- Obstructive jaundice

ImagingIncidental pancreatic mass





**Autoimmune Pancreatitis** 

# **Diagnostic Criteria: II**

Other organ involvement

- Biliary
- Liver
- Kidney
- Lung

Response to steroids



**Autoimmune Pancreatitis** 

## **Patient Characteristics**


Gender

• Male > female

Age • Wide range (20-80 years), most > 50 years Comorbidity • Autoimmune diseases











Tsiotos, 2002 Lankisch PG, Pancreatology 2001; 1:3